Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel
NASDAQ:IMUX

Immunic Q1 2025 Earnings Results & Report

Immunic logo
$6.88 -0.02 (-0.22%)
As of 09:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunic met analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$2.50 versus the -$2.50 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Immunic EPS Results

Actual EPS
-$2.50
Consensus EPS
-$2.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Immunic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Immunic's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunic's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Immunic Q1 2025 Earnings FAQ

Immunic (NASDAQ:IMUX) reported earnings of -$2.50 per share for Q1 2025, matching the consensus estimate of -$2.50. The report was announced on Thursday, May 15, 2025.

Immunic's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunic on the company's earnings history page.

Immunic Earnings Headlines

Stifel Nicolaus Remains a Buy on Immunic (IMUX)
October 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/IMUX/pressreleases/5354282/stifel-nicolaus-remains-a-buy-on-immunic-imux/
Immunic (NASDAQ:IMUX) Stock Bumped Down to "Sell" by Wall Street Zen
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104280
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 the 10th Joint ACTRIMS-ECTRIMS Meeting
October 8, 2026  |  marketscreener.comM
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
October 7, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1099751?snapi
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
October 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immunic-to-present-new-clinical-biomarker-and-preclinical-data-on-vidofludimus-calcium-at-mstoronto2026--the-10th-joint-actrims-ectrims-meeting-302901094.html
See More Immunic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunic and other key companies, straight to your email.

About Immunic

Immunic (NASDAQ:IMUX) is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease. Immunic is also advancing earlier-stage programs such as IMU-856, which targets Sirtuin 6 and is being evaluated for intestinal disorders, and IMU-381, an investigational molecule intended for immune-mediated diseases.

Immunic was established in 2016 and became a publicly traded company in 2019 through a merger with Vital Therapies, subsequently adopting the Immunic name. The company maintains operations in the United States and Germany, including corporate activities in Waltham, Massachusetts, and research and development operations in Germany. Its programs are investigational and remain subject to clinical testing and regulatory review.

View Immunic Profile
Earnings Tools